Top

CNS Drugs

Published in:

01-10-2012 | Current Opinion

Further Findings Linking SSRIs During Pregnancy and Persistent Pulmonary Hypertension of the Newborn

Clinical Implications

Authors: Dr Megan Galbally, Salvatore Gentile, Andrew J. Lewis

Published in: CNS Drugs | Issue 10/2012

Abstract

Persistent pulmonary hypertension of the newborn (PPHN) is a rare but potentially life-threatening neonatal condition. Several authors have suggested that late pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs) may increase the risk of PPHN. This association has been investigated in seven published studies that have shown mixed findings based on diverse methods. Several methodological limitations may account for the diversity of findings, which include, in some studies, a lack of control for well established risk factors for PPHN. The methodological improvement in the most recent study tentatively suggests that infants prenatally exposed to SSRIs are approximately twice as likely to suffer PPHN. Further research on the biological mechanisms involved is required. Clinicians should consider late pregnancy exposure to SSRIs as one of several possible risks for PPHN, which has implications for both prescribing SSRIs to pregnant women and for neonatal care of SSRI-exposed infants.

Hernandez-Diaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007; 120(2): e272–82CrossRefPubMed

Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol 2005; 29(1): 8–15CrossRefPubMed

Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry 2012 Feb; 169(2): 134–40CrossRefPubMed

Graves E, Redmond C, Arensman RM. Persistent pulmonary hypertension in the neonate. Chest 1988; 93(3): 638–41CrossRefPubMed

Field D, Davis C, Elbourne D, et al. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Int J Gynecol Obstet 1996; 55(3): 314–5

Hansen AK, Wisborg K, Uldbjerg N, et al. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ 2008; 336(7635): 85–7CrossRefPubMed

Hansen AK, Wisborg K, Uldbjerg N, et al. Elective caesarean section and respiratory morbidity in the term and nearterm neonate. Acta Obstet Gynecol Scand 2007; 86(4): 389–94CrossRefPubMed

Maschi S, Clavenna A, Campi R, et al. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008 Jan; 115(2): 283–9CrossRefPubMed

Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006 Feb 9; 354(6): 579–87CrossRefPubMed

10.

Fornaro E, Li D, Pan J, et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007 Nov 15; 176(10): 1035–40CrossRefPubMed

11.

Lim K, Sanders A, Brain U, et al. Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev 2012; 88(8): 609–15CrossRefPubMed

12.

Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996 Oct 3; 335(14): 1010–5CrossRefPubMed

13.

Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008 Aug; 17(8): 801–6CrossRefPubMed

14.

Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010 Oct; 40(10): 1723–33CrossRefPubMed

15.

Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009; 84(1): 23–7CrossRefPubMed

16.

Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009 Mar; 18(3): 246–52CrossRefPubMed

17.

Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011; 28(1): 19–24CrossRefPubMed

18.

Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344: d8012CrossRefPubMed

19.

Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105(1): 14–20CrossRefPubMed

20.

Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160(2): 173–6CrossRefPubMed

21.

Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry 2009 Sep; 43(9): 846–54CrossRefPubMed

22.

Gentile S. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 2010; 15(3): 167–85PubMed

23.

Oberlander T, Bonaguro R, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2007; 13(1): 65–73CrossRefPubMed

24.

Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008 May; 192(5): 338–43CrossRefPubMed

25.

Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114(5): 1297–304CrossRefPubMed

26.

Everson SA, Maty SC, Lynch JW, et al. Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J Psychosom Res 2002; 53(4): 891–5CrossRefPubMed

27.

Linares Scott TJ, Heil SH, Higgins ST, et al. Depressive symptoms predict smoking status among pregnant women. Addict Behav 2009 Aug; 34(8): 705–8CrossRefPubMed

28.

Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118(1): 111–20CrossRefPubMed

29.

Austin MP, Kildea S, Sullivan E. Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust 2007 Apr 2; 186(7): 364–7PubMed

30.

Bansil P, Kuklina EV, Meikle SF, et al. Maternal and fetal outcomes among women with depression. J Womens Health (Larchmt) 2010 Feb; 19(2): 329–34CrossRef

31.

Brettingham M. Depression and obesity are major causes of maternal death in Britain. BMJ 2004 Nov 20; 329 (7476): 1205CrossRefPubMed

32.

Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004 Nov; 49(11): 726–35PubMed

33.

Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000 Apr; 95(4): 487–90CrossRefPubMed

34.

Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG 2008 Jul; 115(8): 1043–51CrossRefPubMed

35.

Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002 Nov; 159(11): 1889–95CrossRefPubMed

36.

Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006 Feb 1; 295(5): 499–507CrossRefPubMed

37.

Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011 Nov; 22(6): 848–54PubMed

38.

Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009 Oct; 163(10): 949–54CrossRefPubMed

39.

Suri R, Altshuler L, Hellemann G, et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007 Aug; 164(8): 1206–13CrossRefPubMed

40.

Ramos E, St-Andre M, Berard A. Association between antidepressant use during pregnancy and infants born small for gestational age. Can J Psychiatry 2010 Oct; 55(10): 643–52PubMed

41.

Lewis AJ, Galbally M, Opie G, et al. Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication. Aust N Z J Psychiatry 2010 May; 44(5): 482–7CrossRefPubMed

42.

Galbally M, Lewis AJ, Buist A. Developmental outcomes of children exposed to antidepressants in pregnancy. Aust N Z J Psychiatry 2011 May; 45(5): 393–9CrossRefPubMed

43.

Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003 Apr; 142(4): 402–8CrossRefPubMed

44.

Van den Bergh BR, Van Calster B, Smits T, et al. Antenatal maternal anxiety is related to HPA-axis dysregulation and self-reported depressive symptoms in adolescence: a prospective study on the fetal origins of depressed mood. Neuropsychopharmacology 2008 Feb; 33(3): 536–45CrossRefPubMed

45.

Galbally M, Lewis AJ, Gentile S, et al. The biology of fetal exposure to serotonin reuptake inhibitors: implications for neurodevelopment. In: Migne LJ, Post JW, editors. Antidepressants: pharmacology, health effects and controversy. New York (NY), USA: Nova, 2012: 1–26

46.

Van den Bergh BRH, Mulder EJH, Mennes M, et al. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. Neurosci Biobehav Rev 2005; 29(2): 237–58CrossRefPubMed

47.

Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Focus 2009; 7(3): 374–84

48.

Fox WW, Duara S. Persistent pulmonary hypertension in the neonate: diagnosis and management. J Pediatr 1983; 103(4): 505–14CrossRefPubMed

49.

Galbally M, Snellen M, Lewis AJ. A review of the use of psychotropic medication in pregnancy. Curr Opin Obstet Gynecol 2011; 23(6): 408–14CrossRefPubMed

50.

Galbally M, Snellen M, Walker S, et al. Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care. Aust N Z J Psychiatry 2010 Feb; 44(2): 99–108CrossRefPubMed

Title: Further Findings Linking SSRIs During Pregnancy and Persistent Pulmonary Hypertension of the Newborn
Clinical Implications
Authors: Dr Megan Galbally
Salvatore Gentile
Andrew J. Lewis
Publication date: 01-10-2012
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 10/2012
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11630310-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Further Findings Linking SSRIs During Pregnancy and Persistent Pulmonary Hypertension of the Newborn

Clinical Implications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2012

Acute Treatment of Migraines

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

Oromucosal Midazolam: A Guide to Its Use in Paediatric Patients with Prolonged Acute Convulsive Seizures

Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder

Alteplase

Frontotemporal Lobar Degeneration